Moderna Inc. closed $127.61 below its 52-week high ($170.47), which the company achieved on May 24th.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data ...

Shares of Moderna Inc. MRNA slipped 9.07% to $41.51 Tuesday, on what proved to be an all-around grim trading session for the ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines ...

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

The S&P 500 fell 0.3% on Tuesday, Dec. 10, as the cooldown from last week's record-setting rally continued ahead of key ...